Drug Trial Radar · NCT05259917
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Last checked: Nov 19, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
136
Actual
Start
Feb 22, 2022
Primary completion
Dec 31, 2023
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult Patients
Conditions
- Hereditary Angioedema
Interventions
PlaceboDrug
Placebo to KVD900 Tablet
KVD900 600 mgDrug
KVD900 Tablet 600 mg (2 x 300 mg)
KVD900 300 mgDrug
KVD900 Tablet 300 mg (1 x 300 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Beginning of Symptom Relief Patient Global Impression of Change (PGI-C)Time frame: Within 12 hours of the first investigational medicinal product (IMP) administration.
Locations
66 sites in 21 countries. Site status is shown where the registry gives one.
KalVista Investigative Site
Birmingham, Alabama
KalVista Investigative Site
Scottsdale, Arizona
KalVista Investigative Site
Little Rock, Arkansas
KalVista Investigative Site
San Diego, California
KalVista Investigative Site
San Diego, California
KalVista Investigative Site
Santa Monica, California
KalVista Investigative Site
Centennial, Colorado
KalVista Investigative Site
Colorado Springs, Colorado
KalVista Investigative Site
Tampa, Florida
KalVista Investigative Site
Chicago, Illinois
KalVista Investigative Site
Overland Park, Kansas
KalVista Investigative Site
Louisville, Kentucky
KalVista Investigative Site
Chevy Chase, Maryland
KalVista Investigative Site
Plymouth, Minnesota
KalVista Investigative Site
St Louis, Missouri
KalVista Investigative Site
New York, New York
KalVista Investigative Site
Charlotte, North Carolina
KalVista Investigative Site
Toledo, Ohio
KalVista Investigative Site
Hershey, Pennsylvania
KalVista Investigative Site
Dallas, Texas
KalVista Investigative Site
Layton, Utah
KalVista Investigative Site
Spokane, Washington
KalVista Investigative Site
Campbelltown, New South Wales, Australia
KalVista Investigative Site
Sofia, Bulgaria
KalVista Investigative Site
Toronto, Ontario, Canada
KalVista Investigative Site
Grenoble, France
KalVista Investigative Site
Lille, France
KalVista Investigative Site
Lille, France
KalVista Investigative Site
Paris, France
KalVista Investigative Site
Berlin, Germany
KalVista Investigative Site
Mainz, Germany
KalVista Investigative Site
Mörfelden-Walldorf, Germany
KalVista Investigative Site
Frankfurt am Main, Hesse, Germany
Kalvista Investigative Site
Athens, Greece
KalVista Investigative Site
Athens, Greece
KalVista Investigative Site
Budapest, Hungary
KalVista Investigative Site
Haifa, Israel
KalVista Investigative Site
Petach Tikvah, Israel
KalVista Investigative Site
Ramat Gan, Israel
KalVista Investigative Site
Tel Aviv, Israel
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.